| Literature DB >> 35370954 |
Rongrong Zhou1, Yashan Cui2, Yuehong Zhang1, Jin De1, Xuedong An1, Yingying Duan3, Yuqing Zhang1, Xiaomin Kang2, Fengmei Lian1.
Abstract
Objective: This study aimed at examining the long-term effects of non-pharmacological interventions on reducing the diabetes incidence among patients with prediabetes and chronic complications events among patients with hyperglycemia (pre-diabetes and diabetes) by performing a systematic review and meta-analysis of randomized controlled trials (RCTs).Entities:
Keywords: complications; diabetes incidence; long-term; meta-analysis; non-pharmacological intervention; randomized controlled trial
Mesh:
Year: 2022 PMID: 35370954 PMCID: PMC8971720 DOI: 10.3389/fendo.2022.838224
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1The flow diagram of search and selection process used for studies included in the meta-analysis.
The main characteristics of eligible articles included in the meta-analysis.
| Study | First author (year) | Country | Participants | I (number) | C (number) | Outcomes of I | Outcomes of C | Duration of intervention | Duration of extended follow-up | Total length | Diagnostic criteria |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Pan (1997) ( | China | IGT | Lifestyle intervention (diet and exercise) (397) | Standard care (133) | 52 T2DM | 30 T2DM | 6 years | 0 year | 6 years | WHO 1985 |
| Gong (2011) ( | Lifestyle intervention (409) | Standard care (133) | 309 DM; 66 MVD | 118 DM; 26 MVD | 6 years | 14 years | 20 years | ||||
|
| Ranchamdran (2013) ( | India | IGT | Mobile phone messaging of lifestyle modification (271) | Standard care (266) | 50 T2DM | 73 T2DM | 2 years | 0 year | 2 years | WHO 1999 |
| Nanditha (2018) ( | Mobile phone messaging of lifestyle modification (183) | Standard care (163) | 29 DM | 33 DM | 2 years | 3 years | 5 years | ||||
|
| Lindström (2006) ( | Finnish | IGT | Lifestyle 265 | Standard Care 257 | 44 DM | 76 DM | 4 years | 0 year | 4 years | WHO 1985 |
| Lifestyle 238 | Standard Care 237 | 75 DM | 110 DM | 4 years | 3 years | 7 years | |||||
| Aro (2019) ( | Lifestyle intervention (113) | Control group (98) | 27 MVD | 37 MVD | 4 years | 5 years | 9 years | ||||
|
| Knowler (2002) ( | American | PDM | Intensive lifestyle intervention (1079) | Placebo (1082) | 155 DM | 313 DM | 2.8 years | 0 year | 2.8 years | ADA |
| The Diabetes Prevention Program Research Group (2015) ( | Lifestyle intervention (751) | Metformin with placebo (1552) | 103 MVD | 236 MVD | 10 years | 0 year | 10 years | ||||
|
| Penn (2009) ( | The UK | IGT | Individual motivational interviewing (39) | Usual care (38) | 5 T2DM | 11 T2DM | 3.1 years | 0 year | 3.1 years | WHO 1999 |
|
| Roumen (2008) ( | Netherlands | IGT | Lifestyle intervention (44) | Usual care (47) | 8 T2DM | 18 T2DM | 3 years | 0 year | 3 years | WHO 1999 |
|
| Davies (2016) ( | The UK | PDM | Lifestyle intervention (356) | Standard care (360) | 64 T2DM | 67 T2DM | 3 years | 0 year | 3 years | WHO 1990 |
|
| Balducci (2006) ( | Italy | DM | Exercise training (31) | Sedentary lifestyle (47) | 4 DPN | 10 DPN | 4 years | 0 year | 4 years | Feldman et al., 1994 |
|
| Kosaka (2005) ( | Japan | IGT | Lifestyle 102 | Standard Care 356 | 3 DM | 33 DM | 4 years | 0 years | 4 years | WHO1980 |
|
| Ranchamdran (2006) ( | India | IGT | Lifestyle intervention (120) | Control group (382) | 47 T2DM | 173 T2DM | 3 years | 0 year | 3 years | WHO 1999 |
|
| Liao (2002) ( | USA | IGT | Lifestyle (36) | Control (38) | 1 DM | 2 DM | 2 years | 0 year | 2 years | WHO 1985 |
|
| Lindahl (2009) ( | Sweden | IGT | Lifestyle (83) | Usual care (85) | 17 DM | 23 DM | 5 years | 0 year | 5 years | WHO 1985 |
|
| Saito (2011) ( | Japan | IFG | Lifestyle (311) | Control (330) | 35 DM | 51 DM | 3 years | 0 year | 3 years | WHO 1999 |
|
| Sakane (2011) ( | Japan | IGT | Lifestyle (152) | Control (152) | 9 DM | 18 DM | 3 years | 0 year | 3 years | WHO 1985 |
|
| Zong (2015) ( | China | PDM | Nutrition (107) | Control (107) | 3 DM | 11 DM | 2 years | 0 year | 2 years | WHO 1985 |
|
| Hellgren (2016) ( | Sweden | PDM | Physical activity (66) | Usual care (30) | 10 DM | 7 DM | 3 years | 0 year | 3 years | IDF 2011 |
I, Intervention group; C, Control group; ADA, American Diabetes Association; WHO, World Health Organization; DPP, The American Diabetes Prevention Study; DPS, The Finnish Diabetes Prevention Study; SLIM, The Maastricht Diabetes Prevention Study; IGT, impaired glucose tolerance; DM, diabetes mellitus; T2DM, type 2 diabetes mellitus; DR, diabetic retinopathy; DN, diabetic nephropathy; DPN, diabetic peripheral neuropathy; PD, pre-diabetes mellitus; CVD, cardiovascular disease; MVD, microvascular disease.
Figure 2Forest plot of diabetes incidence in intervention studies.
Figure 3Forest plot of microvascular events.
The sensitivity analysis outcomes of microvascular events.
| Removal of study | Intervention, N | Control, N | Pooled effect estimate | Heterogeneity | |||
|---|---|---|---|---|---|---|---|
| RR | 95% Cl | p-value | I2 | pZ | |||
| None | 0 | 0 | 0.60 | [0.43, 0.83] | 0.06 | 60% | 0.002 |
| Aro, 2019 ( | 27/113 | 37/98 | 0.59 | [0.37, 0.95] | 0.04 | 70% | 0.03 |
| Balducci, 2006 ( | 4/31 | 10/47 | 0.60 | [0.41, 0.87] | 0.02 | 73% | 0.008 |
| Gong, 2011 ( | 66/409 | 26/133 | 0.49 | [0.40, 0.61] | 0.34 | 7% | 0.0001 |
| The Diabetes Prevention ProgramResearch Group, 2015 ( | 103/751 | 236/780 | 0.72 | [0.54, 0.95] | 0.64 | 0% | 0.02 |
Figure 4Forest plot of diabetes incidence in extended follow-up studies.
The sensitivity analysis outcomes of diabetes incidence in extended follow-up studies.
| Removal of study | Intervention, N | Control, N | Pooled effect estimate | Heterogeneity | |||
|---|---|---|---|---|---|---|---|
| RR | 95% Cl | p-value | I2 | pZ | |||
| None | 0 | 0 | 0.78 | [0.63, 0.96] | 0.07 | 62% | 0.02 |
| Gong, 2011 ( | 309/409 | 118/133 | 0.70 | [0.57, 0.86] | 0.58 | 0% | 0.0007 |
| Lindström, 2006 ( | 75/238 | 110/237 | 0.85 | [0.78, 0.92] | 0.66 | 0% | <0.0001 |
| Nanditha, 2018 ( | 29/183 | 33/163 | 0.78 | [0.59, 1.02] | 0.02 | 81% | 0.07 |
Figure 5Forest plot of subgroup analysis of diabetes incidence in intervention studies.
Quality of bias assessment of the included studies according to Cochrane guidelines.
| First author (year) | Sequence generation | Allocation concealment | Blinding of participants, personnel, and outcome | Incomplete outcome data | Selective outcome reporting | Other potential threats to validity |
|---|---|---|---|---|---|---|
| Pan, 1997 ( | L | L | H | L | L | L |
| Gong, 2011 ( | L | L | H | L | L | L |
| Ramachandran, 2013 ( | L | L | H | L | L | L |
| Nanditha, 2018 ( | L | L | H | L | L | L |
| Lindström, 2006 ( | L | L | H | L | L | L |
| Aro, 2019 ( | L | L | H | L | L | L |
| Knowler, 2002 ( | L | L | L | L | L | L |
| The Diabetes Prevention Program Research Group, 2015 ( | L | L | H | L | L | L |
| Penn, 2009 ( | L | L | H | L | L | L |
| Roumen, 2008 ( | L | L | H | L | L | L |
| Davies, 2016 ( | L | L | H | L | L | L |
| Balducci, 2006 ( | L | L | H | L | L | L |
| Kosaka, 2005 ( | L | L | H | L | L | L |
| Ramachandran, 2006 ( | L | L | H | L | L | L |
| Liao, 2002 ( | L | L | H | L | L | L |
| Lindahl, 2009 ( | L | L | H | L | L | L |
| Saito, 2011 ( | L | L | H | L | L | L |
| Sakane, 2011 ( | L | L | H | L | L | L |
| Zong, 2015 ( | L | L | U | L | L | L |
| Hellgren, 2016 ( | L | L | U | L | L | L |
L, low risk of bias; H, high risk of bias; U, unclear risk of bias.